Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

H. Alexander, John; D. Lópes, Renato; James, Stefan; Kilaru, Rakhi; He, Yaohua; Mohan, Puneet; L. Bhatt, Deepak; G. Goodman, Shaun; W.A. Verheugt, Freek; Flather, Marcus; Huber, Kurt; Liaw, Danny; Husted, Steen; López‐Sendón, José; De Caterina, Raffaele; Janský, Petr; Darius, Harald; Vinereanu, Dragoş; H. Cornel, Jan; Cools, Frank; Atar, Dan; L. Leiva-Pons, José; Keltai, Mátyás; Ogawa, Hisao; Pais, Prem; Parkhomenko, Alexander; Rużyłło, Witold; Díaz, Rafael; D. White, Harvey; Ruda, Mikhail; Geraldes, Margarida; Lawrence, Jack; A. Harrington, Robert; Wallentin, Lars

doi:10.1056/nejmoa1105819

Public

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome

Published in New England Journal of Medicine • Jul 24, 2011

Authors:

John H. Alexander

Renato D. Lópes

Stefan James

Abstract

BACKGROUND: Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. METHODS: We conducted a randomized, double-blind, placebo-controlled clinical trial comparing apixaban, at a dose of 5 mg t...

Subject

Acute coronary syndrome

Apixaban

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!